Nick Bartz, Imaging Peformance Partnership
Late last week, CMS and the HHS Office of the National Coordinator for HIT released their final ruling for Stage 2 of the Medicare/Medicaid Electronic Health Record Incentives Program, commonly referred to as “meaningful use” (MU).
Amongst other changes, the rule confirms a possible payment adjustment exemption for radiologists depending on their scope of practice, a new optional imaging-specific MU measure, and provides more detail on how radiologists should define patient encounters.
Though the Partnership will release a full analysis in the coming weeks, we've identified the top three insights for radiologists and imaging leaders.
CMS releases Stage 2 final rule for meaningful use
Matthew Morril, Technology Insights
While demographic trends are placing a larger burden on hospital resources, capital budgets continue to tighten in the wake of reform. Administrators may seek to control costs by extending the useful lives of clinical technology and equipment, which could save millions of dollars if done prudently and deliberately.
However, hospital administrators must be cautious to find the balance between conserving capital and meeting the clinical standard of care by offering key innovations. Ultimately, administrators must balance several factors—such as cost of maintenance, downtime, and tradeoffs in technological advances—when making decisions to extend the lifecycles of their imaging equipment.
In case you missed it: Maximizing your imaging equipment lifecycles
Stephanie Krent, Imaging Performance Partnership
New developments in lung cancer CT screening have given many hope that doctors can find the disease, responsible for over one million deaths annually, early enough to successfully treat it. But widespread implementation of screening programs hinges on the determination of high-risk patient populations.
Now, researchers from the Liverpool Lung Project believe their risk stratification model can bridge the gap.
Liverpool Lung Project: A new way to personalize cancer risk